Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms COBRRA
- 04 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Sep 2017.
- 04 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.